Ilya Pharma have had a successful preIND meeting with the FDA related to the development of ILP100-Oral
The company have successfully conducted a preIND Type B meeting with the FDA regarding its developments of ILP100-Oral for the planned clinical development in cancer patients with colitis as a result of their cancer treatment. Today 30-40% of cancer patients receiving treatment with immune checkpoint inhibitors (ICIs) have to discontinue the treatment due to colitis. The Company is currently preparing the IND according to plan.